News

Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue (21 June 2012)

Read the full announcement in PDF format

Novo Nordisk today announced the decision to initiate the global phase 3 development programme for semaglutide, a once-weekly human GLP-1 (Glucagon-Like Peptide-1) analogue.

Further information:

Media: Investors:
Mike Rulis Kasper Roseeuw Poulsen
Tel: (+45) 3079 3573 Tel: (+45) 4442 4303
mike@novonordisk.com krop@novonordisk.com
Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com
Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbpj@novonordisk.com
In North America:
Ken Inchausti Jannick Lindegaard
Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575
kiau@novonordisk.com jlis@novonordisk.com

Company announcement No 40 / 2012

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •